NCT04541706 2024-12-20Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaPfizerPhase 4 Completed100 enrolled 10 charts
NCT00652561 2024-09-03Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung CancerTaiho Oncology, Inc.Phase 2 Completed57 enrolled